Anti-GABAbR antibody positivity in a patient with hereditary diffuse leukoencephalopathy with spheroids (HDLS): a case report

preprint OA: closed
Full text JSON View at publisher

Abstract

Background: Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS), a rare autosomal dominant inherited leukodystrophy, is associated with the genetic mutations of colony stimulating factor 1 receptor (CSF1R). The clinical manifestations may be a combination of mental, neurological and physical symptoms that are easily misdiagnosed. And the magnetic resonance imaging (MRI) showed asymmetric white matter damage. Case presentation: We report a case which genetically confirmed hereditary diffuse leukoencephalopathy with spheroids with anti-GABAbR antibody positivity. A 30-year-old woman presented with a 30-month history of progressive limb weakness, aphasia, stiff and cognitive decline. Brain MRI revealed persistent white matter hyperintensities on diffusion-weighted images for 24 months. Sequence analysis of CSF1R showed a novel missense mutation c.1736G>A (p.R579Q). The presence of anti-GABAbR antibody did not report in patients with HDLS. After immunoglobulin and methylprednisolone steroid pulse therapy, the patient's condition improved and the Barthel index scale of daily living ability was increased from 40 to 60. Conclusions: HDLS is often misdiagnosed due to the diverse clinical manifestations and the lack of reliable laboratory indicators. The case may helpful for clinicians to further understand the disease. If a patient whose manifestations are progressive limb weakness and cognitive impairment with anti-GABAbR antibody positivity and the MRI shows asymmetric white matter damage, clinicians should consider the possibility of HDLS and recommend genetic testing.
Full text 43,144 characters · extracted from preprint-html · click to expand
Anti-GABAbR antibody positivity in a patient with hereditary diffuse leukoencephalopathy with spheroids (HDLS): a case report | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Case report Anti-GABAbR antibody positivity in a patient with hereditary diffuse leukoencephalopathy with spheroids (HDLS): a case report Hongyu Cao, Lei Yang, Ling Yu, Wei Qin, Juan Zhang, Yue Li, Shuna Yang, and 1 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.2.9165/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background: Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS), a rare autosomal dominant inherited leukodystrophy, is associated with the genetic mutations of colony stimulating factor 1 receptor (CSF1R). The clinical manifestations may be a combination of mental, neurological and physical symptoms that are easily misdiagnosed. And the magnetic resonance imaging (MRI) showed asymmetric white matter damage. Case presentation: We report a case which genetically confirmed hereditary diffuse leukoencephalopathy with spheroids with anti-GABAbR antibody positivity. A 30-year-old woman presented with a 30-month history of progressive limb weakness, aphasia, stiff and cognitive decline. Brain MRI revealed persistent white matter hyperintensities on diffusion-weighted images for 24 months. Sequence analysis of CSF1R showed a novel missense mutation c.1736G>A (p.R579Q). The presence of anti-GABAbR antibody did not report in patients with HDLS. After immunoglobulin and methylprednisolone steroid pulse therapy, the patient's condition improved and the Barthel index scale of daily living ability was increased from 40 to 60. Conclusions: HDLS is often misdiagnosed due to the diverse clinical manifestations and the lack of reliable laboratory indicators. The case may helpful for clinicians to further understand the disease. If a patient whose manifestations are progressive limb weakness and cognitive impairment with anti-GABAbR antibody positivity and the MRI shows asymmetric white matter damage, clinicians should consider the possibility of HDLS and recommend genetic testing. Internal Medicine Specialties Hereditary diffuse leukoencephalopathy with spheroids Colony stimulating factor 1 receptor Diffusion-weighted imaging anti-GABAbR antibody Figures Figure 1 Figure 2 Background Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) is a rare autosomal dominant inherited leukodystrophy, which was first reported by Axelsson in 1984.1 The magnetic resonance imaging (MRI) showed asymmetric white matter damage. Clinical manifestations may be a combination of psychiatric, neurological, and somatic symptoms1 and easy to be misdiagnosed. It's been proven that the only pathogenic gene of HDLS is colony stimulating factor 1 receptor (CSF1R) gene. The impact on tyrosine kinase domain caused by CSF1R gene mutation is the basis of white matter disease of HDLS.2 And more than 50 mutations in the HDLS patients have been reported up to now,including missense, frameshift and nonsense mutations, but also deletions and splice-site mutations, all mutations are located in the intracellular tyrosine kinase domain, encoded by exons 12-22.3 Here, we report a young female patient diagnosed HDLS with a new mutation of whom anti- GABAbR antibodies were detected. Case presentation A 30-year-old, right-handed female patient admitted to our hospital for a 30-month history of progressive limbs weakness, aphasia and cognitive decline on June 27, 2016. At the beginning of the course of her disease, she showed only poor right-hand flexibility and was diagnosed with stroke, but the antiplatelet therapy was ineffective. Then she got a little bit of walking instability, pronouncing unclearly and drinking choked occasionally. The thoracic spine enhanced MRI showed abnormal intramedullary signals without enhancement on C6-T1 segment which referred to demyelination, the cervical spine enhanced MRI showed C5-6 intervertebral disc protrusion. According to these results, the doctor thought she probablely had inflammatory demyelination of the central nervous system,but cerebral autosomal dominant arteriopathy with subcortical infarcts leukoencephalopathy (CADASIL) cannot be excluded. The patient began to get worse and the limbs became weakness on March 2015. At the end of 2015, her legs were too weak to walk, and she slurred more serious. Three months later, she developed into mixed aphasia. Since illness, she frequently appeared forced laughing and had poor sleep. The urinary and fecal incontinence occurred occasionally. Except a history of mumps at age 3, there is no history of other common diseases and genetic disease, and her families were not affected. But her menstrual cycle is irregular. At the time of admission, her vital signs were normal. Because of aphasia, a complete neuropsychological test could not be performed. The pupil and eye movements are normal. She had the right side of limb weakness of grade 4 and bilateral pyramidal signs were positive. She didn’t have sensory disturbance. After admission, MRI showed multiple asymmetric hyperintense signal changes with no enhancement on DWI (Figure 1), and the ventricles are clearly dilated. The cerebrospinal fluid (CSF) examination revealed no obvious signs of inflammation and evidence of pathogen infection except leucocyte increased mildly (19/ul). But we found the anti-GABAbR antibody positivity in CSF. Therefore, we given the methylprednisolone and gamma globulin. The patient developed skin rash all over the body and got alleviated after treatment. Immunological examination showed positive anti-nuclear antibody (1:100). The laboratory tests for leukocyte, liver function, kidney function, prothrombin time and partial thromboplastin time were normal. Syphilis and HIV serology was negative. Dynamic erythrocyte sedimentation rate was faster than normal (25 mm/h). Cardiac evaluation including electrocardiogram and heart ultrasound was normal. Genetic testing revealed the presence of a heterozygous mutation c.1736G>A in the CSF1R gene leading to a change in the corresponding amino acid sequence (p.R579Q)(Figure 2). Based on the clinical manifestations, imaging characteristics and genetic analysis of the patient, we diagnosed HDLS. And we treated her with immunoglobulin (5 days) and methylprednisolone steroids (2 weeks). After two weeks of treatment, the patient's symptoms improved and the Barthel index scale of daily living ability was increased from 40 to 60. Because the patient was bedridden for a long time, she could not come to the hospital for a check. We only know from her father that she is currently completely aphasic and unable to take care of herself completely. Discussion and Conclusions HDLS is a rare autosomal dominant inherited leukodystrophy. The average age of onset is about 40 years (18-72 years), with a course of disease ranging from 2-30 years.3 The clinical symptoms and signs include3, 4: (1) impairment of higher cortical function (abnormal mental behavior, personality changes, cognitive dysfunction); (2) motor and sensory disturbances; (3) symptoms of Parkinson's disease and dystonia; (4) cerebellar and brainstem symptom. MRI showed asymmetric white matter damage without enhancement, especially the frontal and parietal lobes, and the corticospinal tract is normally involved at the middle and late stages. With the white matter damage deteriorated, the ventricles may become enlarged and cause secondary brain atrophy change.5 The MRI findings of our patient were basically consistent with these manifestations. The severity of HDLS can be assessed using a total MRI severity score (0-57), according to the rating system, HDLS is divided into 3 grades: mild(1-6), moderate(7-15) and severe (16-57) .5 In addition, Some studies have found that patients with HDLS shown lower concentration of N-acetylaspartate (NAA) and glutamate (Glu), and higher concentration of choline-containing compounds (Cho) and myo-inositol (Ins) on magnetic resonance spectroscopy (MRS).6 This may be related to nerve damage and glial cell hyperplasia leading to decreased neurotransmitters. HDLS is caused by mutations in the protein tyrosine kinase domain of the CSF1R, encoded by the CSF1R gene on chromosome 5q32.2. Before the pathogenic gene has been found, the only way to diagnose HDLS is pathologic examination of leukodystrophy, where axonal spheroid changes are demonstrated either by brain biopsy or by autopsy.1, 4 The histopathological features of the white matter lesion area were changes in axonal spheroid, myelin deleted, proliferative pigmented microglia which expressed CSF1R poorly, and lipid-rich macrophages.7, 8 The typical electron microscopy examination appearance of HDLS is axonal swelling, fulling of neurofilament arranged in a jumbled pattern and vacuolations of myelin sheath or demyelination and capillary basal lamina dilated. Postmortem examination showed that the microglia cells in the white matter were not evenly distributed, and the content of microglia-related proteins was reduced. 9 Immunohistochemical staining showed positive results of neurofilaments (NF), amyloid precursor protein (APP) and ubiquitin.10 Unfortunately, for economic reasons, our patient did not undergo pathological examination. The main manifestations of this female patient is progressive limb weakness, slurred speech and cognitive impairment, consistent with previous reports.3 MRI-DWI showed multiple high signals of white matter and bilateral ventricles in bilateral frontal cortex, accompanied by diffuse high signals of white matter and corpus callosum,which was consistent with the imaging manifestations of typical HDLS. However, we first found a new gene mutation of HDLS, genetic analysis confirmed a novel heterozygous c.1736G>A mutation resulting in a R579Q substitution in exon 12. This mutation was not recorded in the Human Gene Mutation Database (HGMD). And there was no mutation frequency data in the normal population. This mutation may explain the positive anti-GABAbR antibody with HDLS. At the same time, the laboratory examination found that patients with anti-nuclear antibody positive (1:100), may be associated with genetic mutations can lead to immune abnormalities. Regrettably, the patient refused a biopsy, and we could not learn more about the pathological changes. Therefore, the possibility of HDLS should be considered in patients with anti-GABAbR antibody positive combined with leukodystrophy. From the perspective of imaging, CADASIL presented extensive white matter high signal in the brain with subcortical infarction, so our patient was suspected of CADASIL initially,but CADASIL can be detected with Notch3 gene mutation.11 Notably, HDLS was misdiagnosed as atypical Parkinson's,4 dementia (including Alzheimer's disease and frontotemporal dementia)12 and primary progressive multiple sclerosis (PPMS)13 in previous reports. In conclusion, HDLS is often misdiagnosed due to the diverse clinical manifestations and the lack of reliable laboratory indicators. For patients with leukodystrophy, particularly with anti-GABAbR antibody positivity, and the clinical manifestations include dyskinesia, behavioral cognitive changes, Parkinson's syndrome, and psychiatric symptoms, doctors should consider the possibility of HDLS, and advise patients and their family members to perform genetic tests in order to make a clear diagnosis and reduce the birth of children with genetic defects through genetic counseling. Further studies are necessary to better understand the physiology-pathologic effects of CSF-1R mutations and the detailed molecular mechanisms leading to HDLS. Notes Hongyu Cao and Lei Yang are joint first authors. Two authors have the same initials (LY) in the Authors’ Contributions section, with LY1 corresponding to Lei Yang, with LY2 corresponding to Ling Yu. List of abbreviations HDLS: Hereditary diffuse leukoencephalopathy with axonal spheroids CSF1R: colony stimulating factor 1 receptor CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts leukoencephalopathy CSF: cerebrospinal fluid HGMD: Human Gene Mutation Database APP: amyloid precursor protein PPMS: primary progressive multiple sclerosis Declarations Ethics approval and consent to participate The study was approved by the Institutional Ethical Committee of Beijing Chaoyang Hospital, Capital Medical University and the patient gave written informed consent prior to obtain the data. Consent for publication Written informed consent was obtained from the patient after treatment for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. Availability of data and materials All data for this case report are included in this article. Competing interests The authors declare that they have no competing interests. Funding Not applicable. Authors’ contributions LY1 and HYC examined, evaluated the patient and drafted the manuscript. LY2, WQ and JZ analyzed the genetic test report, YL and SNY performed and interpreted the MRI studies. WLH participated in the design of the case-report and helped to draft the manuscript. All authors read and approved the final manuscript. Acknowledgements Not applicable. References 1. Axelsson R, Roytta M, Sourander P, Akesson HO, Andersen O. Hereditary diffuse leucoencephalopathy with spheroids. Acta Psychiatr Scand Suppl. 1984;314:1-65. 2. Rademakers R, Baker M, Nicholson AM, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet. Dec 25 2011;44(2):200-205. 3. Stabile C, Taglia I, Battisti C, Bianchi S, Federico A. Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): update on molecular genetics. Neurol Sci. Sep 2016;37(9):1565-1569. 4. Sundal C, Lash J, Aasly J, et al. Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): a misdiagnosed disease entity. J Neurol Sci. Mar 15 2012;314(1-2):130-137. 5. Sundal C, Van Gerpen JA, Nicholson AM, et al. MRI characteristics and scoring in HDLS due to CSF1R gene mutations. Neurology. Aug 7 2012;79(6):566-574. 6. Abe T, Kawarai T, Fujita K, et al. MR Spectroscopy in Patients with Hereditary Diffuse Leukoencephalopathy with Spheroids and Asymptomatic Carriers of Colony-stimulating Factor 1 Receptor Mutation. Magn Reson Med Sci. Oct 10 2017;16(4):297-303. 7. Jin C, Washimi Y, Yoshida K, Hashizume Y, Yazawa I. Characterization of spheroids in hereditary diffuse leukoencephalopathy with axonal spheroids. J Neurol Sci. May 15 2015;352(1-2):74-78. 8. Riku Y, Ando T, Goto Y, et al. Early pathologic changes in hereditary diffuse leukoencephalopathy with spheroids. J Neuropathol Exp Neurol. Dec 2014;73(12):1183-1190. 9. Tada M, Konno T, Tada M, et al. Characteristic microglial features in patients with hereditary diffuse leukoencephalopathy with spheroids. Ann Neurol. Oct 2016;80(4):554-565. 10. Lin WL, Wszolek ZK, Dickson DW. Hereditary diffuse leukoencephalopathy with spheroids: ultrastructural and immunoelectron microscopic studies. Int J Clin Exp Pathol. Jul 26 2010;3(7):665-674. 11. Wang MM. CADASIL. Handb Clin Neurol. 2018;148:733-743. 12. Ahmed R, Guerreiro R, Rohrer JD, et al. A novel A781V mutation in the CSF1R gene causes hereditary diffuse leucoencephalopathy with axonal spheroids. J Neurol Sci. Sep 15 2013;332(1-2):141-144. 13. Sundal C, Baker M, Karrenbauer V, et al. Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. Eur J Neurol. Feb 2015;22(2):328-333. Supplementary Files supplement1.doc Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-611","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Case report","associatedPublications":[],"authors":[{"id":82673,"identity":"0022e391-44b3-4b6d-bd64-1f2f15f28719","order_by":1,"name":"Hongyu Cao","email":"","orcid":"","institution":"Beijing Chaoyang Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Hongyu","middleName":"","lastName":"Cao","suffix":""},{"id":82674,"identity":"6030ee95-5219-4949-87fb-b460676fc74b","order_by":2,"name":"Lei Yang","email":"","orcid":"","institution":"Beijing Chaoyang Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Lei","middleName":"","lastName":"Yang","suffix":""},{"id":82675,"identity":"64b83643-4d4e-4c92-92b1-38c4fcf564af","order_by":3,"name":"Ling Yu","email":"","orcid":"","institution":"Beijing Chaoyang Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Ling","middleName":"","lastName":"Yu","suffix":""},{"id":82676,"identity":"6dacd00d-b43a-4f9a-ac57-b206e3e2225d","order_by":4,"name":"Wei Qin","email":"","orcid":"","institution":"Beijing Chaoyang Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Wei","middleName":"","lastName":"Qin","suffix":""},{"id":82677,"identity":"743f6e67-f163-489f-aada-b5306e4d3851","order_by":5,"name":"Juan Zhang","email":"","orcid":"","institution":"Beijing Chaoyang Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Juan","middleName":"","lastName":"Zhang","suffix":""},{"id":82678,"identity":"cdad1868-da66-4eed-ab44-4d7b9089b9a6","order_by":6,"name":"Yue Li","email":"","orcid":"","institution":"Beijing Chaoyang Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yue","middleName":"","lastName":"Li","suffix":""},{"id":82679,"identity":"348096c1-f0b2-4aff-845b-17f26ee8425b","order_by":7,"name":"Shuna Yang","email":"","orcid":"","institution":"Beijing Chaoyang Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Shuna","middleName":"","lastName":"Yang","suffix":""},{"id":82680,"identity":"b8a6d61b-871b-436a-b6b0-3bdac5f7d389","order_by":8,"name":"Wen Li Hu","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA0UlEQVRIiWNgGAWjYHACxgOJDQx28uzNBx8kVNgQpwekJdmw51iywYMzaURqYWxgYGy44aMm+bDtEGHlBsd7Dxx4uOMwM+MMHraKBLYDDPzt3Qn4tZw5l3Ag8cxhPnbp3mM3EnjuMEicObsBrxazGzkGBxLbgLbMOZd2I0HiGYOBRC4BLfffgLUA/ZJjVpBgcJgILTd4EFoYEhKI0GJ/BuywdHAgSyQcSOMh6BfJ9jOGD3+2WYOj8uPPfzZy/O29+LVgAB7SlI+CUTAKRsEowAoAExJVpqfebm0AAAAASUVORK5CYII=","orcid":"","institution":"Beijing Chaoyang Hospital","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Wen","middleName":"Li","lastName":"Hu","suffix":""}],"badges":[],"createdAt":"2019-04-12 15:18:12","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.2.9165/v1","doiUrl":"https://doi.org/10.21203/rs.2.9165/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":2610782,"identity":"6f64429e-723b-4362-adaf-53d0493a7b64","added_by":"b0e95e7b-bbe0-4bfd-bf12-a325b7db0c3e","created_at":"2020-09-25 20:51:51","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":445331,"visible":true,"origin":"","legend":"MRI showed multiple asymmetric hyperintense signal changes with no enhancement on DWI.","description":"","filename":"figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-611/v1/figure_1.png"},{"id":2610774,"identity":"f31cd4d1-48f1-4db7-9a2c-dade071dff55","added_by":"b0e95e7b-bbe0-4bfd-bf12-a325b7db0c3e","created_at":"2020-09-25 20:51:51","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":40432,"visible":true,"origin":"","legend":"Gene analysis of CSF1R. A heterozygous c.1736G\u003eA (p.R579Q) mutation in exon 12 of CSF1R was found in this patient (arrow).","description":"","filename":"figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-611/v1/figure_2.png"},{"id":13466576,"identity":"eb46e444-6354-4138-94d6-2dd32d47c252","added_by":"auto","created_at":"2021-09-16 20:51:28","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":650459,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-611/v1/0a8069c9-b2e6-4044-a258-2148ad4480be.pdf"},{"id":2610776,"identity":"0a35869a-2838-4f98-b37f-6ac287f4a910","added_by":"b0e95e7b-bbe0-4bfd-bf12-a325b7db0c3e","created_at":"2020-09-25 20:51:51","extension":"doc","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":182272,"visible":true,"origin":"","legend":"","description":"","filename":"supplement1.doc","url":"https://assets-eu.researchsquare.com/files/rs-611/v1/supplement_1.doc"}],"financialInterests":"","formattedTitle":"Anti-GABAbR antibody positivity in a patient with hereditary diffuse leukoencephalopathy with spheroids (HDLS): a case report","fulltext":[{"header":"Background","content":"\u003cp\u003eHereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) is a rare autosomal dominant inherited leukodystrophy, which was first reported by Axelsson in 1984.1 The magnetic resonance imaging (MRI) showed asymmetric white matter damage. Clinical manifestations may be a combination of psychiatric, neurological, and somatic symptoms1 and easy to be misdiagnosed. It's been proven that the only pathogenic gene of HDLS is colony stimulating factor 1 receptor (CSF1R) gene. The impact on tyrosine kinase domain caused by CSF1R gene mutation is the basis of white matter disease of HDLS.2 And more than 50 mutations in the HDLS patients have been reported up to now,including missense, frameshift and nonsense mutations, but also deletions and splice-site mutations, all mutations are located in the intracellular tyrosine kinase domain, encoded by exons 12-22.3 Here, we report a young female patient diagnosed HDLS with a new mutation of whom anti- GABAbR antibodies were detected. \u003c/p\u003e"},{"header":"Case presentation","content":"\u003cp\u003eA 30-year-old, right-handed female patient admitted to our hospital for a 30-month history of progressive limbs weakness, aphasia and cognitive decline on June 27, 2016. At the beginning of the course of her disease, she showed only poor right-hand flexibility and was diagnosed with stroke, but the antiplatelet therapy was ineffective. Then she got a little bit of walking instability, pronouncing unclearly and drinking choked occasionally. The thoracic spine enhanced MRI showed abnormal intramedullary signals without enhancement on C6-T1 segment which referred to demyelination, the cervical spine enhanced MRI showed C5-6 intervertebral disc protrusion. According to these results, the doctor thought she probablely had inflammatory demyelination of the central nervous system,but cerebral autosomal dominant arteriopathy with subcortical infarcts leukoencephalopathy (CADASIL) cannot be excluded. The patient began to get worse and the limbs became weakness on March 2015. At the end of 2015, her legs were too weak to walk, and she slurred more serious. Three months later, she developed into mixed aphasia. Since illness, she frequently appeared forced laughing and had poor sleep. The urinary and fecal incontinence occurred occasionally. Except a history of mumps at age 3, there is no history of other common diseases and genetic disease, and her families were not affected. But her menstrual cycle is irregular. At the time of admission, her vital signs were normal. Because of aphasia, a complete neuropsychological test could not be performed. The pupil and eye movements are normal. She had the right side of limb weakness of grade 4 and bilateral pyramidal signs were positive. She didn’t have sensory disturbance.\u003c/p\u003e\n\u003cp\u003eAfter admission, MRI showed multiple asymmetric hyperintense signal changes with no enhancement on DWI (Figure 1), and the ventricles are clearly dilated. The cerebrospinal fluid (CSF) examination revealed no obvious signs of inflammation and evidence of pathogen infection except leucocyte increased mildly (19/ul). But we found the anti-GABAbR antibody positivity in CSF. Therefore, we given the methylprednisolone and gamma globulin. The patient developed skin rash all over the body and got alleviated after treatment. Immunological examination showed positive anti-nuclear antibody (1:100). The laboratory tests for leukocyte, liver function, kidney function, prothrombin time and partial thromboplastin time were normal. Syphilis and HIV serology was negative. Dynamic erythrocyte sedimentation rate was faster than normal (25 mm/h). Cardiac evaluation including electrocardiogram and heart ultrasound was normal. Genetic testing revealed the presence of a heterozygous mutation c.1736G\u0026gt;A in the CSF1R gene leading to a change in the corresponding amino acid sequence (p.R579Q)(Figure 2). Based on the clinical manifestations, imaging characteristics and genetic analysis of the patient, we diagnosed HDLS. And we treated her with immunoglobulin (5 days) and methylprednisolone steroids (2 weeks). After two weeks of treatment, the patient's symptoms improved and the Barthel index scale of daily living ability was increased from 40 to 60.\u003c/p\u003e\n\u003cp\u003e Because the patient was bedridden for a long time, she could not come to the hospital for a check. We only know from her father that she is currently completely aphasic and unable to take care of herself completely. \u003c/p\u003e"},{"header":"Discussion and Conclusions","content":"\u003cp\u003eHDLS is a rare autosomal dominant inherited leukodystrophy. The average age of onset is about 40 years (18-72 years), with a course of disease ranging from 2-30 years.3 The clinical symptoms and signs include3, 4: (1) impairment of higher cortical function (abnormal mental behavior, personality changes, cognitive dysfunction); (2) motor and sensory disturbances; (3) symptoms of Parkinson's disease and dystonia; (4) cerebellar and brainstem symptom. MRI showed asymmetric white matter damage without enhancement, especially the frontal and parietal lobes, and the corticospinal tract is normally involved at the middle and late stages. With the white matter damage deteriorated, the ventricles may become enlarged and cause secondary brain atrophy change.5 The MRI findings of our patient were basically consistent with these manifestations. The severity of HDLS can be assessed using a total MRI severity score (0-57), according to the rating system, HDLS is divided into 3 grades: mild(1-6), moderate(7-15) and severe (16-57) .5 In addition, Some studies have found that patients with HDLS shown lower concentration of N-acetylaspartate (NAA) and glutamate (Glu), and higher concentration of choline-containing compounds (Cho) and myo-inositol (Ins) on magnetic resonance spectroscopy (MRS).6 This may be related to nerve damage and glial cell hyperplasia leading to decreased neurotransmitters.\u003c/p\u003e\n\u003cp\u003eHDLS is caused by mutations in the protein tyrosine kinase domain of the CSF1R, encoded by the CSF1R gene on chromosome 5q32.2. Before the pathogenic gene has been found, the only way to diagnose HDLS is pathologic examination of leukodystrophy, where axonal spheroid changes are demonstrated either by brain biopsy or by autopsy.1, 4 The histopathological features of the white matter lesion area were changes in axonal spheroid, myelin deleted, proliferative pigmented microglia which expressed CSF1R poorly, and lipid-rich macrophages.7, 8 The typical electron microscopy examination appearance of HDLS is axonal swelling, fulling of neurofilament arranged in a jumbled pattern and vacuolations of myelin sheath or demyelination and capillary basal lamina dilated. Postmortem examination showed that the microglia cells in the white matter were not evenly distributed, and the content of microglia-related proteins was reduced. 9 Immunohistochemical staining showed positive results of neurofilaments (NF), amyloid precursor protein (APP) and ubiquitin.10 Unfortunately, for economic reasons, our patient did not undergo pathological examination.\u003c/p\u003e\n\u003cp\u003eThe main manifestations of this female patient is progressive limb weakness, slurred speech and cognitive impairment, consistent with previous reports.3 MRI-DWI showed multiple high signals of white matter and bilateral ventricles in bilateral frontal cortex, accompanied by diffuse high signals of white matter and corpus callosum,which was consistent with the imaging manifestations of typical HDLS. However, we first found a new gene mutation of HDLS, genetic analysis confirmed a novel heterozygous c.1736G\u0026gt;A mutation resulting in a R579Q substitution in exon 12. This mutation was not recorded in the Human Gene Mutation Database (HGMD). And there was no mutation frequency data in the normal population. This mutation may explain the positive anti-GABAbR antibody with HDLS. At the same time, the laboratory examination found that patients with anti-nuclear antibody positive (1:100), may be associated with genetic mutations can lead to immune abnormalities. Regrettably, the patient refused a biopsy, and we could not learn more about the pathological changes. Therefore, the possibility of HDLS should be considered in patients with anti-GABAbR antibody positive combined with leukodystrophy. From the perspective of imaging, CADASIL presented extensive white matter high signal in the brain with subcortical infarction, so our patient was suspected of CADASIL initially,but CADASIL can be detected with Notch3 gene mutation.11 Notably, HDLS was misdiagnosed as atypical Parkinson's,4 dementia (including Alzheimer's disease and frontotemporal dementia)12 and primary progressive multiple sclerosis (PPMS)13 in previous reports.\u003c/p\u003e\n\u003cp\u003eIn conclusion, HDLS is often misdiagnosed due to the diverse clinical manifestations and the lack of reliable laboratory indicators. For patients with leukodystrophy, particularly with anti-GABAbR antibody positivity, and the clinical manifestations include dyskinesia, behavioral cognitive changes, Parkinson's syndrome, and psychiatric symptoms, doctors should consider the possibility of HDLS, and advise patients and their family members to perform genetic tests in order to make a clear diagnosis and reduce the birth of children with genetic defects through genetic counseling. Further studies are necessary to better understand the physiology-pathologic effects of CSF-1R mutations and the detailed molecular mechanisms leading to HDLS.\u003c/p\u003e"},{"header":"Notes","content":"\u003cp\u003eHongyu Cao and Lei Yang are joint first authors.\u003c/p\u003e\n\u003cp\u003e\u003ca name=\"OLE_LINK60\"/\u003e\u003ca name=\"OLE_LINK61\"/\u003eTwo authors have the same initials (LY) in the Authors’ Contributions section, with LY1 corresponding to Lei Yang, with LY2 corresponding to Ling Yu.\u003c/p\u003e"},{"header":"List of abbreviations","content":"\u003cp\u003eHDLS: Hereditary diffuse leukoencephalopathy with axonal spheroids\u003c/p\u003e\n\u003cp\u003eCSF1R: colony stimulating factor 1 receptor\u003c/p\u003e\n\u003cp\u003eCADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts leukoencephalopathy\u003c/p\u003e\n\u003cp\u003eCSF: cerebrospinal fluid\u003c/p\u003e\n\u003cp\u003eHGMD: Human Gene Mutation Database \u003c/p\u003e\n\u003cp\u003eAPP: amyloid precursor protein\u003c/p\u003e\n\u003cp\u003ePPMS: primary progressive multiple sclerosis\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cb\u003eEthics approval and consent to participate\u003c/b\u003e\u003c/p\u003e\n\u003cp\u003eThe study was approved by the Institutional Ethical Committee of Beijing Chaoyang Hospital, Capital Medical University and the patient gave written informed consent prior to obtain the data.\u003c/p\u003e\n\u003cp\u003e\u003cb\u003eConsent for publication\u003c/b\u003e\u003c/p\u003e\n\u003cp\u003eWritten informed consent was obtained from the patient after treatment for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal. \u003c/p\u003e\n\u003cp\u003e\u003cb\u003eAvailability of data and materials\u003c/b\u003e\u003c/p\u003e\n\u003cp\u003eAll data for this case report are included in this article. \u003c/p\u003e\n\u003cp\u003e\u003cb\u003eCompeting interests\u003c/b\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca name=\"_Hlk1659539\"/\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cb\u003eFunding\u003c/b\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cb\u003eAuthors’ contributions\u003c/b\u003e\u003c/p\u003e\n\u003cp\u003e\u003ca name=\"OLE_LINK58\"/\u003e\u003ca name=\"OLE_LINK59\"/\u003eLY1 and HYC examined, evaluated the patient and drafted the manuscript. LY2, WQ and JZ analyzed the genetic test report, YL and SNY performed and interpreted the MRI studies. WLH participated in the design of the case-report and helped to draft the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp/\u003e\n\u003cp\u003e\u003cb\u003eAcknowledgements\u003c/b\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e"},{"header":"References","content":"\u003cp class=\"list_Paragraph\"\u003e1. Axelsson R, Roytta M, Sourander P, Akesson HO, Andersen O. Hereditary diffuse leucoencephalopathy with spheroids. \u003ci\u003eActa Psychiatr Scand Suppl. \u003c/i\u003e1984;314:1-65.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e2. Rademakers R, Baker M, Nicholson AM, et al. Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. \u003ci\u003eNat Genet. \u003c/i\u003eDec 25 2011;44(2):200-205.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e3. Stabile C, Taglia I, Battisti C, Bianchi S, Federico A. Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): update on molecular genetics. \u003ci\u003eNeurol Sci. \u003c/i\u003eSep 2016;37(9):1565-1569.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e4. Sundal C, Lash J, Aasly J, et al. Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): a misdiagnosed disease entity. \u003ci\u003eJ Neurol Sci. \u003c/i\u003eMar 15 2012;314(1-2):130-137.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e5. Sundal C, Van Gerpen JA, Nicholson AM, et al. MRI characteristics and scoring in HDLS due to CSF1R gene mutations. \u003ci\u003eNeurology. \u003c/i\u003eAug 7 2012;79(6):566-574.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e6. \u003ca name=\"OLE_LINK56\"/\u003eAbe T, Kawarai T, Fujita K, et al. MR Spectroscopy in Patients with Hereditary Diffuse Leukoencephalopathy with Spheroids and Asymptomatic Carriers of Colony-stimulating Factor 1 Receptor Mutation. \u003ci\u003eMagn Reson Med Sci. \u003c/i\u003eOct 10 2017;16(4):297-303.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e7. Jin C, Washimi Y, Yoshida K, Hashizume Y, Yazawa I. Characterization of spheroids in hereditary diffuse leukoencephalopathy with axonal spheroids. \u003ci\u003eJ Neurol Sci. \u003c/i\u003eMay 15 2015;352(1-2):74-78.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e8. Riku Y, Ando T, Goto Y, et al. Early pathologic changes in hereditary diffuse leukoencephalopathy with spheroids. \u003ci\u003eJ Neuropathol Exp Neurol. \u003c/i\u003eDec 2014;73(12):1183-1190.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e9. Tada M, Konno T, Tada M, et al. Characteristic microglial features in patients with hereditary diffuse leukoencephalopathy with spheroids. \u003ci\u003eAnn Neurol. \u003c/i\u003eOct 2016;80(4):554-565.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e10. Lin WL, Wszolek ZK, Dickson DW. Hereditary diffuse leukoencephalopathy with spheroids: ultrastructural and immunoelectron microscopic studies. \u003ci\u003eInt J Clin Exp Pathol. \u003c/i\u003eJul 26 2010;3(7):665-674.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e11. Wang MM. CADASIL. \u003ci\u003eHandb Clin Neurol. \u003c/i\u003e2018;148:733-743.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e12. Ahmed R, Guerreiro R, Rohrer JD, et al. A novel A781V mutation in the CSF1R gene causes hereditary diffuse leucoencephalopathy with axonal spheroids. \u003ci\u003eJ Neurol Sci. \u003c/i\u003eSep 15 2013;332(1-2):141-144.\u003c/p\u003e\n\u003cp class=\"list_Paragraph\"\u003e13. Sundal C, Baker M, Karrenbauer V, et al. Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. \u003ci\u003eEur J Neurol. \u003c/i\u003eFeb 2015;22(2):328-333.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Hereditary diffuse leukoencephalopathy with spheroids; Colony stimulating factor 1 receptor; Diffusion-weighted imaging; anti-GABAbR antibody","lastPublishedDoi":"10.21203/rs.2.9165/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.2.9165/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"Background: Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS), a rare autosomal dominant inherited leukodystrophy, is associated with the genetic mutations of colony stimulating factor 1 receptor (CSF1R). The clinical manifestations may be a combination of mental, neurological and physical symptoms that are easily misdiagnosed. And the magnetic resonance imaging (MRI) showed asymmetric white matter damage.\nCase presentation: We report a case which genetically confirmed hereditary diffuse leukoencephalopathy with spheroids with anti-GABAbR antibody positivity. A 30-year-old woman presented with a 30-month history of progressive limb weakness, aphasia, stiff and cognitive decline. Brain MRI revealed persistent white matter hyperintensities on diffusion-weighted images for 24 months. Sequence analysis of CSF1R showed a novel missense mutation c.1736G\u003eA (p.R579Q). The presence of anti-GABAbR antibody did not report in patients with HDLS. After immunoglobulin and methylprednisolone steroid pulse therapy, the patient's condition improved and the Barthel index scale of daily living ability was increased from 40 to 60.\nConclusions: HDLS is often misdiagnosed due to the diverse clinical manifestations and the lack of reliable laboratory indicators. The case may helpful for clinicians to further understand the disease. If a patient whose manifestations are progressive limb weakness and cognitive impairment with anti-GABAbR antibody positivity and the MRI shows asymmetric white matter damage, clinicians should consider the possibility of HDLS and recommend genetic testing.","manuscriptTitle":"Anti-GABAbR antibody positivity in a patient with hereditary diffuse leukoencephalopathy with spheroids (HDLS): a case report","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2019-04-15 13:44:21","doi":"10.21203/rs.2.9165/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"639abe01-27d7-4b29-8c94-5ffeef6272d1","owner":[],"postedDate":"April 15th, 2019","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":11338,"name":"Internal Medicine Specialties"}],"tags":[],"updatedAt":"","versionOfRecord":[],"versionCreatedAt":"2019-04-15 13:44:21","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-611","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"identity":"rs-611","version":["v1"]},"buildId":"ApUGefWb6u5IBVtyqm6d5","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: preprint-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00